Program
nerandomilast
Also written as “BI 1015550”, “Nerandomilast” and “Nerandomilast formulation 1”.
Its studies are mostly in Lung Diseases, Interstitial · Idiopathic Pulmonary Fibrosis · Myositis · Scleroderma, Systemic · Amyotrophic Lateral Sclerosis, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 347 open or running | phase 3since Apr 4, 2022 | May 7, 2012 | Apr 15, 2027phase 3 · NCT06806592 |
| Gipfel Life Sciences | 11 open or running | phase 3since Jan 2, 2026 | Jan 2, 2026 | Jun 30, 2027phase 3 · NCT07321860 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 19 studies since May 7, 2012.
- Nov 15, 2023Phase 1 study in HealthyBoehringer Ingelheim · NCT06139302 · 12 enrolled · Japan
- Jan 25, 2024Phase 3 study in Idiopathic Pulmonary FibrosisBoehringer Ingelheim · NCT06238622 · 1,666 enrolled · United States, Argentina, Australia and more
- Jan 29, 2024Phase 2 study in Idiopathic Pulmonary FibrosisBoehringer Ingelheim · NCT06241560 · 20 enrolled · United States, Georgia
- Apr 29, 2024Phase 1 study in HealthyBoehringer Ingelheim · NCT06393127 · 64 enrolled · Germany
- May 7, 20242 phase 1 studies in HealthyBoehringer Ingelheim · NCT06408870, NCT06415045
- Oct 1, 2024Phase 1 study in HealthyBoehringer Ingelheim · NCT06624072 · 15 enrolled · Germany
- Jan 28, 2025Phase 3 study in Lung Diseases, InterstitialBoehringer Ingelheim · NCT06806592 · 414 enrolled · United States, Australia, Austria and more
- Jul 22, 20252 phase 1 studies in HealthyBoehringer Ingelheim · NCT07081932, NCT07100964
- Sep 30, 2025Phase 3 study in Lung Diseases, InterstitialBoehringer Ingelheim · NCT07201922 · 80 planned · United States, Argentina, Australia and more
- Jan 2, 2026Gipfel Life Sciences's first study: phase 3 study in Amyotrophic Lateral SclerosisNew to Gipfel Life SciencesGipfel Life Sciences · NCT07321860 · 60 planned
- Jan 23, 2026Phase 3 study in Fibrosing Interstitial Lung DiseaseBoehringer Ingelheim · NCT07366034 · 35 planned · United States, Argentina, Australia and more
- Mar 23, 2026Phase 3 study in Scleroderma, SystemicBoehringer Ingelheim · NCT07497087 · 448 planned · United States, Argentina, Australia and more
- Apr 15, 2026Phase 3 study in Lung Diseases, InterstitialBoehringer Ingelheim · NCT07540988 · 466 planned · United States, Argentina, Australia and more
- Aug 24, 2026Phase 3 study in MyositisBoehringer Ingelheim · NCT07789015 · 270 planned · United States, Argentina, Australia and more
Ahead
- Apr 15, 2027Primary completion: phase 3 study in Lung Diseases, InterstitialBoehringer Ingelheim · NCT06806592
- Apr 28, 2027Primary completion: phase 3 study in Idiopathic Pulmonary FibrosisBoehringer Ingelheim · NCT06238622
- Jun 30, 2027Primary completion: phase 3 study in Amyotrophic Lateral SclerosisGipfel Life Sciences · NCT07321860
- Dec 5, 2028Primary completion: phase 3 study in Lung Diseases, InterstitialBoehringer Ingelheim · NCT07540988
TargetBeta
“Meanwhile, nerandomilast, a selective PDE4B inhibitor, elevates intracellular cAMP in immune and glial cells, shifting pro-inflammatory signaling toward resolution and antagonizing secondary fibrotic and inflammatory cascades.”study text, by rule · the study
Other programs on PDE4B
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Roflumilastrule | AstraZeneca | phase 4 | 61 |
| apremilastrule | Amgen | phase 4 | 48 |
| ensifentrinerule | Merck | phase 3 | 17 |
| difamilastrule | Otsuka | phase 3 | 16 |
| tanimilastrule | Chiesi Farmaceutici | phase 3 | 15 |
Studies
All 35 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07789015Myositis · United States, Argentina, Australia and more | 3 | Not yet recruiting | Boehringer Ingelheim | Mar 21, 2030 | 270 |
| NCT07540988Lung Diseases, Interstitial · United States, Argentina, Australia and more | 3 | Recruiting | Boehringer Ingelheim | Dec 5, 2028 | 466 |
| NCT07497087Scleroderma, Systemic · United States, Argentina, Australia and more | 3 | Recruiting | Boehringer Ingelheim | Feb 26, 2030 | 448 |
| NCT07366034Fibrosing Interstitial Lung Disease · United States, Argentina, Australia and more | 3 | Recruiting | Boehringer Ingelheim | Apr 27, 2029 | 35 |
| NCT07321860Amyotrophic Lateral Sclerosis | 3 | Not yet recruiting | Gipfel Life Sciences | Jun 30, 2027 | 60 |
| NCT07201922Lung Diseases, Interstitial · United States, Argentina, Australia and more | 3 | Recruiting | Boehringer Ingelheim | May 14, 2029 | 80 |
| NCT07100964Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Sep 20, 2025 | 16 |
| NCT07081932Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Sep 27, 2025 | 16 |
| NCT06806592Lung Diseases, Interstitial · United States, Australia, Austria and more | 3 | Active, not recruiting | Boehringer Ingelheim | Apr 15, 2027 | 414 |
| NCT06624072Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Nov 22, 2024 | 15 |
| NCT06415045Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jul 24, 2024 | 18 |
| NCT06408870Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Aug 28, 2024 | 64 |
| NCT06393127Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Sep 10, 2024 | 64 |
| NCT06241560Idiopathic Pulmonary Fibrosis · United States, Georgia | 2 | Completed | Boehringer Ingelheim | Aug 5, 2026 | 20 |
| NCT06238622Idiopathic Pulmonary Fibrosis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Boehringer Ingelheim | Apr 28, 2027 | 1,666 |
| NCT06139302Healthy · Japan | 1 | Completed | Boehringer Ingelheim | Feb 7, 2024 | 12 |
| NCT06107036Healthy · United Kingdom | 1 | Completed | Boehringer Ingelheim | Jul 25, 2024 | 46 |
| NCT06070610Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Dec 14, 2023 | 14 |
| NCT05718648Renal Insufficiency · Germany | 1 | Completed | Boehringer Ingelheim | Aug 15, 2023 | 26 |
| NCT05707403Healthy · Netherlands | 1 | Completed | Boehringer Ingelheim | Mar 28, 2023 | 8 |
| NCT05661344Hepatic Insufficiency · Germany | 1 | Completed | Boehringer Ingelheim | Sep 13, 2023 | 28 |
| NCT05633862Healthy · China | 1 | Completed | Boehringer Ingelheim | Mar 16, 2023 | 24 |
| NCT05550636Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Dec 19, 2022 | 15 |
| NCT05428436Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Sep 30, 2022 | 24 |
| NCT05321082Lung Diseases, Interstitial · United States, Argentina, Australia and more | 3 | Completed | Boehringer Ingelheim | Dec 18, 2024 | 1,178 |
| NCT05321069Idiopathic Pulmonary Fibrosis · United States, Argentina, Australia and more | 3 | Completed | Boehringer Ingelheim | Aug 16, 2024 | 1,177 |
| NCT04771286Healthy · Netherlands | 1 | Completed | Boehringer Ingelheim | May 17, 2021 | 6 |
| NCT04419506Idiopathic Pulmonary Fibrosis · United States, Argentina, Australia and more | 2 | Completed | Boehringer Ingelheim | Oct 6, 2021 | 147 |
| NCT03542344Healthy · Japan | 1 | Completed | Boehringer Ingelheim | Aug 24, 2018 | 16 |
| NCT03422068Idiopathic Pulmonary Fibrosis · Denmark, Finland, Germany and more | 1 | Completed | Boehringer Ingelheim | Jul 1, 2019 | 15 |
| NCT03403439Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jul 20, 2018 | 16 |
| NCT03302078Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Dec 13, 2017 | 12 |
| NCT03230487Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jan 16, 2018 | 42 |
| NCT01835899Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jun 2013 | 24 |
| NCT01594515Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Sep 2012 | 70 |
How it is read
Names in the registry
- “BI 1015550”, 27 entries
- “Nerandomilast”, 10 entries
- “Nerandomilast formulation 1”, 1 entry
- “Nerandomilast formulation 2”, 1 entry
- “Nerandomilast 18 mg - adult formulation”, 1 entry
Conditions, from the studies’ own filings
- Lung Diseases, Interstitial, 5 studies
- Idiopathic Pulmonary Fibrosis, 5 studies
- Myositis, 1 study
- Scleroderma, Systemic, 1 study
- Amyotrophic Lateral Sclerosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.